Tg Therapeutics, Inc. (TGTX) Stock Analysis and Metrics

Tg Therapeutics

NASDAQ: TGTX

$56.08 ▲ +0.58 (+1.05%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap8.08 Bn

P/E17.47

P/S11.53

Div. Yield0.00

Total Debt (Qtr)745.14 Mn

Revenue Growth (1y) (Qtr)69.56

Add ratio to table…

About

TG Therapeutics is a fully integrated commercial stage biotechnology company focused on the acquisition development and commercialization of novel treatments for B cell diseases. The company’s lead product BRIUMVI is an anti CD20 monoclonal antibody approved by the FDA in December 2022 for the treatment of adults with relapsing forms of multiple sclerosis including clinically isolated syndrome relapsing remitting disease and active secondary progressive disease. TG Therapeutics advances a pipeline that includes subcutaneous ublituximab being evaluated in a Phase 3 study to compare its exposure to intravenous BRIUMVI and an allogeneic CAR T therapy azer cel targeting CD19 for autoimmune indications such as progressive multiple sclerosis. The subcutaneous ublituximab program aims to offer a less frequent dosing option with regimens of either eight weeks or twelve weeks while the azer cel program leverages donor derived T cells edited with ARCUS technology to avoid graft versus host disease. These efforts are supported by a global network of academic centers and biotech partners from which the company in licenses drug candidates that have shown proof of concept in B cell mediated diseases.

TG Therapeutics generates revenue principally from the sale of BRIUMVI in the United States and from its commercialization agreement with Neuraxpharm for markets outside the United States. Under the agreement TG Therapeutics received an upfront payment of $140 million and a $12.5 million payment upon launch in the first European Union country. The company is eligible to receive up to an additional $492.5 million in milestone payments tied to launch and commercial milestones and will receive tiered double digit royalties on net product sales up to a rate of 30%. TG Therapeutics also earns royalties on BRIUMVI sales under its license with LFB Group at a high single digit rate. Additionally the company may receive milestone payments from its collaboration with Precision for the development of azer cel and could realize future revenue from the commercialization of its pipeline candidates after regulatory approval.

In the multiple sclerosis therapy market TG Therapeutics competes with established anti CD20 antibodies such as ocrelizumab from Roche and ofatumumab from Novartis. Oral therapies including cladribine and dimethyl fumarate as well as emerging Bruton’s tyrosine kinase inhibitors also represent competitive alternatives. TG Therapeutics differentiates BRIUMVI by offering a dosing regimen of a one hour infusion every 24 weeks which provides a less frequent treatment schedule than many competitors. Clinical data from the ULTIMATE I and II trials show that BRIUMVI reduces the annualized relapse rate by approximately 60% compared to teriflunomide and maintains a consistent safety profile over six years of continuous use. The company benefits from patent protection that extends the composition of matter coverage for ublituximab to 2042 and from a twelve year exclusivity period under the Biologics Price Competition and Innovation Act that runs until December 2034. Manufacturing partnerships with Samsung Biologics and FUJIFILM Diosynth Biotechnologies support commercial supply while the company’s focus on B cell diseases allows it to leverage scientific expertise across its pipeline.

TG Therapeutics serves patients living with relapsing forms of multiple sclerosis which includes an estimated one million individuals in the United States and over 2.3 million worldwide. The company’s customers are neurologists multiple sclerosis treatment centers infusion clinics and specialty pharmacy distributors that dispense BRIUMVI to eligible patients. These healthcare providers rely on the product’s convenient dosing schedule and strong efficacy data to manage disease activity and improve patient outcomes. TG Therapeutics also works with advocacy groups and patient organizations to raise awareness and support education about multiple sclerosis and the availability of its therapies.

Investment Thesis

▲ Bull case

TG Therapeutics is positioned to capture significant long-term market share in the relapsing multiple sclerosis (RMS) space through the accelerating adoption of BRIUMVI as a preferred anti-CD20 therapy, driven by its differentiated profile of convenience and tolerability. The company reported Q1 FY25 US net sales of $119.7 million, representing 137% year-over-year growth and 16% sequential quarter-over-quarter growth, well above internal expectations. This momentum is underpinned by real-world evidence showing patients switching from other IV anti-CD20 therapies experience resolution of tolerability issues such as post-infusion malaise and wearing-off effects, which were highlighted in peer-reviewed publications in Frontiers in Immunology and CNS Drugs. These clinical advantages are translating into commercial success, with March marking the highest month ever for repeat prescribers and repeat prescriptions surpassing new prescriptions for the first time—a critical inflection point indicating strong patient persistence at 24 and 48 weeks. The expanding base of loyal prescribers, particularly among high-volume infusion centers and academic institutions, suggests BRIUMVI is becoming the go-to therapy in a competitive landscape, supported by word-of-mouth advocacy within the MS community that management described as powerful and self-reinforcing.
The pipeline of lifecycle innovations for BRIUMVI presents multiple near-term catalysts that could unlock substantial value beyond current sales trajectories, many of which are underappreciated by the market. TG Therapeutics is advancing a pivotal trial for a simplified one-dose initiation regimen (600 mg on day one, eliminating the day 15 dose), expected to start within the next one to three months, which would make BRIUMVI a true twice-a-year therapy from day one and significantly reduce treatment burden. Additionally, the subcutaneous formulation is progressing rapidly, with Phase 1 data showing promising bioavailability supporting every-other-month or quarterly dosing, and the company remains on track to launch a pivotal trial for this version in mid-2025. The subcu BRIUMVI initiative is not merely a formulation change but a strategic platform expansion, with management explicitly citing potential applications in Myasthenia Gravis and other autoimmune indications, leveraging the drug’s mechanism beyond RMS. These innovations could expand the addressable patient pool, improve adherence, and create differentiation in a crowded market, with the subcu version alone representing a potential multi-billion dollar opportunity if successfully commercialized.
TG Therapeutics maintains a resilient financial profile that supports aggressive reinvestment in growth without immediate pressure to achieve profitability, allowing it to prioritize market share capture and pipeline advancement. The company ended Q1 FY25 with $276 million in cash, cash equivalents, and investment securities, providing ample runway to fund operations and strategic initiatives. Despite increased R&D spending—driven by approximately $20 million in manufacturing investments for subcutaneous BRIUMVI—the company reiterated confidence in its full-year OpEx guidance of approximately $300 million, indicating disciplined cost management. Gross-to-net remained stable in the quarter, with management confirming that Part D redesign does not affect BRIUMVI as a Part B drug, and pre-launch reserves have been fully depleted, meaning current gross margins reflect the sustainable run-rate business. Furthermore, the company downplayed tariff risks, noting low cost of goods and manufacturing in South Korea, which minimizes potential impact on profitability. This financial flexibility enables TG to pursue high-impact opportunities like the direct-to-patient television campaign launching in 2025 and continued real-world evidence generation, all while avoiding dilutive financing or premature profit-taking that could hinder long-term value creation.

TG Therapeutics is positioned to capture significant long-term market share in the relapsing multiple sclerosis (RMS) space through the accelerating adoption of BRIUMVI as a preferred anti-CD20 therapy, driven by its differentiated profile of convenience and tolerability. The company reported Q1 FY25 US net sales of $119.7 million, representing 137% year-over-year growth and 16% sequential quarter-over-quarter growth, well above internal expectations. This momentum is underpinned by real-world evidence showing patients switching from other IV anti-CD20 therapies experience resolution of tolerability issues such as post-infusion malaise and wearing-off effects, which were highlighted in peer-reviewed publications in Frontiers in Immunology and CNS Drugs. These clinical advantages are translating into commercial success, with March marking the highest month ever for repeat prescribers and repeat prescriptions surpassing new prescriptions for the first time—a critical inflection point indicating strong patient persistence at 24 and 48 weeks. The expanding base of loyal prescribers, particularly among high-volume infusion centers and academic institutions, suggests BRIUMVI is becoming the go-to therapy in a competitive landscape, supported by word-of-mouth advocacy within the MS community that management described as powerful and self-reinforcing.
The pipeline of lifecycle innovations for BRIUMVI presents multiple near-term catalysts that could unlock substantial value beyond current sales trajectories, many of which are underappreciated by the market. TG Therapeutics is advancing a pivotal trial for a simplified one-dose initiation regimen (600 mg on day one, eliminating the day 15 dose), expected to start within the next one to three months, which would make BRIUMVI a true twice-a-year therapy from day one and significantly reduce treatment burden. Additionally, the subcutaneous formulation is progressing rapidly, with Phase 1 data showing promising bioavailability supporting every-other-month or quarterly dosing, and the company remains on track to launch a pivotal trial for this version in mid-2025. The subcu BRIUMVI initiative is not merely a formulation change but a strategic platform expansion, with management explicitly citing potential applications in Myasthenia Gravis and other autoimmune indications, leveraging the drug’s mechanism beyond RMS. These innovations could expand the addressable patient pool, improve adherence, and create differentiation in a crowded market, with the subcu version alone representing a potential multi-billion dollar opportunity if successfully commercialized.
TG Therapeutics maintains a resilient financial profile that supports aggressive reinvestment in growth without immediate pressure to achieve profitability, allowing it to prioritize market share capture and pipeline advancement. The company ended Q1 FY25 with $276 million in cash, cash equivalents, and investment securities, providing ample runway to fund operations and strategic initiatives. Despite increased R&D spending—driven by approximately $20 million in manufacturing investments for subcutaneous BRIUMVI—the company reiterated confidence in its full-year OpEx guidance of approximately $300 million, indicating disciplined cost management. Gross-to-net remained stable in the quarter, with management confirming that Part D redesign does not affect BRIUMVI as a Part B drug, and pre-launch reserves have been fully depleted, meaning current gross margins reflect the sustainable run-rate business. Furthermore, the company downplayed tariff risks, noting low cost of goods and manufacturing in South Korea, which minimizes potential impact on profitability. This financial flexibility enables TG to pursue high-impact opportunities like the direct-to-patient television campaign launching in 2025 and continued real-world evidence generation, all while avoiding dilutive financing or premature profit-taking that could hinder long-term value creation.

▼ Bear case

TG Therapeutics faces intensifying competitive pressures in the RMS market that may limit its ability to sustain current growth rates, particularly as entrenched competitors leverage scale, pricing power, and new formulations to counter BRIUMVI’s momentum. Despite strong quarterly sales, the company acknowledged it is operating in a highly competitive marketplace and only estimated capturing about 25% of the IV anti-CD20 segment, with no clear path to significantly higher share disclosed. The launch of Roche’s Ocrevus Zunovo—a subcutaneous version of its blockbuster therapy—poses a direct threat to BRIUMVI’s differentiation advantage in convenience, especially if Zunovo demonstrates comparable efficacy and tolerability. Management admitted to seeing “zero impact” from Zunovo thus far, but this may reflect early-stage adoption rather than long-term resilience, particularly given Roche’s extensive MS franchise and commercial infrastructure. Furthermore, while repeat prescriptions have surpassed new prescriptions, the company did not disclose specific persistence rates or cohort data beyond anecdotal feedback, leaving uncertainty about whether the trend reflects genuine durability or early-adopter enthusiasm that could wane as broader patient populations are reached. Without transparent, longitudinal real-world evidence on discontinuation rates or switching behavior beyond initial tolerance improvements, the sustainability of BRIUMVI’s growth remains unproven at scale.
The pipeline catalysts TG Therapeutics is promoting—particularly subcutaneous BRIUMVI and azer-cel—carry significant technical, regulatory, and commercial risks that are not being adequately weighed against their potential upside, creating a risk of overestimation in future growth projections. While management expressed optimism about the subcu formulation’s bioavailability supporting less frequent dosing, they provided no concrete pharmacokinetic data or timelines for when such data would be available, noting only that they are “continuing to collect more data” and will present findings “later this year.” The decision to test both every-other-month and quarterly dosing in the pivotal trial indicates internal uncertainty about the optimal regimen, which could delay approval or result in a less competitive dosing frequency. Similarly, the azer-cel program in progressive MS remains in early Phase 1, with management acknowledging it is “early days for CAR-Ts in autoimmune diseases” and offering no efficacy signals or clinical timelines. The pursuit of Myasthenia Gravis with subcu BRIUMVI is similarly exploratory, with no biomarker strategy, preclinical proof of concept, or defined endpoints disclosed. These initiatives represent speculative bets that could consume substantial R&D capital without near-term returns, especially given the company’s history of prioritizing pipeline expansion over profitability, as evidenced by the CEO’s explicit statement that they are “not prepared to start targeting profitability and earnings per share on an ongoing basis.”
TG Therapeutics’ financial outlook may be overly optimistic due to underappreciated headwinds from gross-to-net pressure, rising operating expenses, and the potential for margin compression as promotional investments scale, despite current reassurances. Although the company raised its full-year 2025 US net revenue guidance to $560 million from $525 million, this increase relies heavily on sustaining the current quarterly growth trajectory, which includes a 16% sequential jump that may not be repeatable given seasonal variability and lapping easier year-over-year comparisons. The CFO acknowledged that OpEx is tracking slightly ahead of the $300 million full-year guidance, driven by front-loaded manufacturing investments for subcu BRIUMVI, and while these costs are expected to fluctuate, there is no guarantee they will decline sufficiently to maintain the annual target. More critically, the company’s push into direct-to-patient advertising—a first-ever television campaign—will likely elevate SG&A expenses meaningfully in the second half of the year, yet no specific OpEx adjustment was provided to reflect this new spend. Without clear visibility into how these rising costs will be offset by incremental revenue, and with management explicitly deprioritizing profitability in favor of revenue growth, there is a risk that losses widen or cash burn accelerates if market share gains fail to meet aggressive expectations, potentially necessitating future financing under less favorable terms.

TG Therapeutics faces intensifying competitive pressures in the RMS market that may limit its ability to sustain current growth rates, particularly as entrenched competitors leverage scale, pricing power, and new formulations to counter BRIUMVI’s momentum. Despite strong quarterly sales, the company acknowledged it is operating in a highly competitive marketplace and only estimated capturing about 25% of the IV anti-CD20 segment, with no clear path to significantly higher share disclosed. The launch of Roche’s Ocrevus Zunovo—a subcutaneous version of its blockbuster therapy—poses a direct threat to BRIUMVI’s differentiation advantage in convenience, especially if Zunovo demonstrates comparable efficacy and tolerability. Management admitted to seeing “zero impact” from Zunovo thus far, but this may reflect early-stage adoption rather than long-term resilience, particularly given Roche’s extensive MS franchise and commercial infrastructure. Furthermore, while repeat prescriptions have surpassed new prescriptions, the company did not disclose specific persistence rates or cohort data beyond anecdotal feedback, leaving uncertainty about whether the trend reflects genuine durability or early-adopter enthusiasm that could wane as broader patient populations are reached. Without transparent, longitudinal real-world evidence on discontinuation rates or switching behavior beyond initial tolerance improvements, the sustainability of BRIUMVI’s growth remains unproven at scale.
The pipeline catalysts TG Therapeutics is promoting—particularly subcutaneous BRIUMVI and azer-cel—carry significant technical, regulatory, and commercial risks that are not being adequately weighed against their potential upside, creating a risk of overestimation in future growth projections. While management expressed optimism about the subcu formulation’s bioavailability supporting less frequent dosing, they provided no concrete pharmacokinetic data or timelines for when such data would be available, noting only that they are “continuing to collect more data” and will present findings “later this year.” The decision to test both every-other-month and quarterly dosing in the pivotal trial indicates internal uncertainty about the optimal regimen, which could delay approval or result in a less competitive dosing frequency. Similarly, the azer-cel program in progressive MS remains in early Phase 1, with management acknowledging it is “early days for CAR-Ts in autoimmune diseases” and offering no efficacy signals or clinical timelines. The pursuit of Myasthenia Gravis with subcu BRIUMVI is similarly exploratory, with no biomarker strategy, preclinical proof of concept, or defined endpoints disclosed. These initiatives represent speculative bets that could consume substantial R&D capital without near-term returns, especially given the company’s history of prioritizing pipeline expansion over profitability, as evidenced by the CEO’s explicit statement that they are “not prepared to start targeting profitability and earnings per share on an ongoing basis.”
TG Therapeutics’ financial outlook may be overly optimistic due to underappreciated headwinds from gross-to-net pressure, rising operating expenses, and the potential for margin compression as promotional investments scale, despite current reassurances. Although the company raised its full-year 2025 US net revenue guidance to $560 million from $525 million, this increase relies heavily on sustaining the current quarterly growth trajectory, which includes a 16% sequential jump that may not be repeatable given seasonal variability and lapping easier year-over-year comparisons. The CFO acknowledged that OpEx is tracking slightly ahead of the $300 million full-year guidance, driven by front-loaded manufacturing investments for subcu BRIUMVI, and while these costs are expected to fluctuate, there is no guarantee they will decline sufficiently to maintain the annual target. More critically, the company’s push into direct-to-patient advertising—a first-ever television campaign—will likely elevate SG&A expenses meaningfully in the second half of the year, yet no specific OpEx adjustment was provided to reflect this new spend. Without clear visibility into how these rising costs will be offset by incremental revenue, and with management explicitly deprioritizing profitability in favor of revenue growth, there is a risk that losses widen or cash burn accelerates if market share gains fail to meet aggressive expectations, potentially necessitating future financing under less favorable terms.

Collaborative Arrangement and Arrangement Other than Collaborative Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Collaborative Arrangement and Arrangement Other than Collaborative Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Collaborative Arrangement and Arrangement Other than Collaborative Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password